Jun 24, 2019

The drug pricing debate steps into the future

Sen. Chuck Grassley. Photo: Win McNamee/Getty Images

The Senate is working on a proposal that would allow state Medicaid programs to pay for new gene therapies over time, and tie those payments to patients' outcomes.

Why it matters: Tying payments to how well drugs work, on this scale, would be an enormous policy change. But some experts are skeptical, saying such a model would perpetuate high prices.

Driving the news: Members of the Senate Finance Committee, led by Chairman Chuck Grassley, are exploring the idea. Grassley considers it a top priority.

  • But no policy has been agreed to, according to a spokesman for Sen. Ron Wyden, the top Democrat on Finance.

How it works: Lawmakers are concerned that high prices and strained state budgets could prevent Medicaid recipients from getting access to new treatments like Zolgensma, a cure for a rare pediatric genetic disease with a $2.1 million price tag.

  • Novartis has said it will accept payment for Zolgensma over 5 years. The Grassley-led proposal would build a similar option into Medicaid, and make it easier to adopt the same model in the private market.
  • The proposal also would require states and drugmakers to agree on clinical benchmarks that must be reached for each payment.
  • Grassley spoke of the proposal in broad strokes last week, and sources familiar provided Axios with more details.

To address concerns that multiyear payment plans would cause manufacturers to inflate their overall price, the total cost of the payments would have to be lower than the price a state would pay all at once.

The other side: Critics have said proposals like this one don’t do enough to tackle drug prices.

  • “These outcomes arrangements may be an attempt to distract from the underlying question of how much a drug should cost when it does work," Peter Bach of the Memorial Sloan Kettering Cancer Center wrote in a recent congressional testimony.
  • Bach is also skeptical of the long-term payment model: “Financing does not reduce total spending, it just changes current obligations," he added.

Go deeper: The real drug pricing debate is upon us

Go deeper

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Global: Total confirmed cases as of 10:30 a.m. ET: 1,363,365— Total deaths: 76,420 — Total recoveries: 292,425Map.
  2. U.S.: Total confirmed cases as of 10:30 a.m. ET: 368,533 — Total deaths: 11,008 — Total recoveries: 19,972Map.
  3. Trump administration latest: Peter Navarro warned White House colleagues in late January about the massive potential risks from the coronavirus.
  4. Public health update: Funeral homes are struggling to handle the pandemic.
  5. 2020 update: Wisconsin Supreme Court blocks the governor's attempt to delay in-person primary voting until June.
  6. Tech update: YouTube has removed thousands of COVID-19 videos for violating policies related to spreading medical misinformation.
  7. What should I do? Pets, moving and personal health. Answers about the virus from Axios expertsWhat to know about social distancingQ&A: Minimizing your coronavirus risk.
  8. Other resources: CDC on how to avoid the virus, what to do if you get it.

Subscribe to Mike Allen's Axios AM to follow our coronavirus coverage each morning from your inbox.

Stephanie Grisham out as White House press secretary

Photo: Chip Somodevilla/Getty Images

White House press secretary Stephanie Grisham is departing her post to return to the East Wing as First Lady Melania Trump's chief of staff, the White House announced Tuesday. The news was first reported by CNN.

Why it matters: Grisham will leave after nine months without ever having held a formal press briefing. Her departure follows the arrival of new White House chief of staff Mark Meadows, who has a chance to overhaul a communications shop that's kept a low profile since President Trump ended the tradition of daily press secretary briefings.

WeWork board sues SoftBank

Illustration: Sarah Grillo/Axios

SoftBank was sued Tuesday morning by a special committee of WeWork's board of directors for alleged breaches of contract and fiduciary duty related to SoftBank's decision to cancel a $3 billion tender offer for WeWork shares.

Why it matters: SoftBank is viewed by many in the private markets as an unfaithful partner. If this reaches trial, that reputation could either become widely cemented or reversed.